Zoom Lacks A Solid Catalyst, Cramer Says: What About Oils? - Eli Lilly ( NYSE:LLY ) , ProFrac Holding ( NASDAQ:ACDC )
On CNBC's "Mad Money Lightning Round," Jim Cramer said that although Zoom Communications Inc. ( NASDAQ:ZM ) is a good company, it lacks a catalyst for recommending it. Therefore, he advises, "take a pass." Zoom Communications will release its financial results for the third quarter on Monday, ...
Here's Why Shares in Viking Therapeutics Shot Higher in October
Three factors took Viking's shares higher in the month.
Billionaire Stanley Druckenmiller Dropped Nvidia and Palantir Stock and Is Piling into 2 Stocks Set to Win in One of the Decade's Hottest Growth Markets.
It's a great idea to watch the latest moves of this expert investor.
Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock?
NVO faces slowing Wegovy and Ozempic momentum, pricing risks and fierce competition ahead of Q3 earnings.
Prediction: The Next Eli Lilly Might Already Be Trading Under $50
Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.
Should You Buy Viking Therapeutics Before Nov. 5?
Viking's stock surged in one trading session after a positive clinical trial report last year.
Where the blockbuster weight loss drug market stands today - and what's coming next
Competition is heating up, but questions remain about insurance coverage, drug pricing, copycat drugs and the role of pills in the space.
3 Promising Growth Stocks That Are Down Around 60% From Their Highs
These stocks may be down as of late, but investors shouldn't count them out in the long run.
Buy, Sell or Hold Lilly Stock? Key Tips Ahead of Q3 Earnings
Eli Lilly's Q3 results hinge on strong demand for Mounjaro and Zepbound as investors weigh growth drivers against the pressure of pricing and competition.
Is Viking Therapeutics ( VKTX ) a Buy as Wall Street Analysts Look Optimistic?
Based on the average brokerage recommendation (ABR), Viking Therapeutics (VKTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
13 Press Releases You Need to See This Week
Including Warner Bros. Discovery's review of strategic options, the results of Crayola's Global Color Vote and 2026's greenest colleges. NEW YORK, Oct. 24, 2025 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire.
Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil
VKTX posts a wider Q3 loss and no sales, as R&D costs surge and obesity drug studies drive spending higher.
Here's Why This Obesity Drug Company's Share Price Soared Today
The company had positive updates on its clinical trials.
Why Is Viking Therapeutics Stock Rising Today? - Viking Therapeutics ( NASDAQ:VKTX )
Shares of Viking Therapeutics, Inc. ( NASDAQ:VKTX ) are rising Thursday. The clinical-stage biopharmaceutical company reported third-quarter earnings and provided updates on clinical trials. VKTX stock is racing ahead of the pack. See the full story here.
Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock?
Lilly stock climbs nearly 10% in a month amid a broader recovery in the drug and biotech sector.
How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q3 Results?
Novo Nordisk's Q3 results hinge on Ozempic and Wegovy sales as demand growth slows amid rivalry, market limits and compounded drug headwinds.
Market Whales and Their Recent Bets on VKTX Options - Viking Therapeutics ( NASDAQ:VKTX )
Investors with a lot of money to spend have taken a bullish stance on Viking Therapeutics ( NASDAQ:VKTX ) . We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we ...
Top Stocks With Earnings This Week: Tesla, Netflix, RTX and More - Tesla ( NASDAQ:TSLA )
Retail investors are preparing for the first busy week in the third-quarter earnings season, with major defense contractors and other top stocks reporting. Here's a look at some retail favorites that individual investors will be watching. TSLA stock is moving. See the real-time price action here.
These 3 Obesity Drug Stocks Are Set to Soar This Fall and Beyond
These companies are jockeying for position in a potential $150 billion market opportunity.
Viking Therapeutics, Inc. ( VKTX ) Stock Dips While Market Gains: Key Facts
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $33.54, denoting a -3.44% move from the preceding trading day.
Pre-Q3 Earnings: Is Viking Therapeutics Stock a Portfolio Must-Have?
VKTX is likely to have headed into Q3 earnings with no product revenue, pipeline updates in focus and widening loss forecasts testing investor patience.
The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, Amgen and Viking Therapeutics
Eli Lilly's blockbuster GLP-1 drugs, Mounjaro and Zepbound, are driving explosive growth as the company prepares to report Q3 results.
Eli Lilly vs. Viking Therapeutics Stock: Which Is the Best Growth Opportunity, According to Wall Street?
These stocks have climbed in the triple digits over the past few years.
NVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease Portfolio
Novo Nordisk's $2.1 billion deal for Omeros' zaltenibart aims to strengthen its rare disease pipeline amid GLP-1 market headwinds.
How Will Mounjaro and Zepbound Sales Aid Lilly's Upcoming Q3 Results?
Strong demand for Mounjaro and Zepbound is expected to power LLY's Q3 growth, as both drugs deepen U.S. and global market reach.
Did Viking Therapeutics Just Say "Checkmate" to Eli Lilly?
The smaller drugmaker is looking to disrupt a fast-growing market.
Viking Therapeutics, Inc. ( VKTX ) Registers a Bigger Fall Than the Market: Important Facts to Note
Viking Therapeutics, Inc. (VKTX) closed at $33.05 in the latest trading session, marking a -2.54% move from the prior day.
Down 44%, Should You Buy the Dip on Viking Therapeutics?
The company is readying to take on pharma giants Novo Nordisk and Eli Lilly.
4 Healthcare Stocks to Buy Now
As investors crowd into AI names at record highs, these three healthcare stocks offer more compelling valuations.
Can Novo Nordisk's Aggressive Deal-Making Offset Semaglutide Reliance?
NVO's $4.7B acquisition of Akero Therapeutics adds a late-stage MASH therapy to its obesity-linked pipeline, advancing its expansion goal beyond semaglutide.
Why Shares in Viking Therapeutics Surged This Week
The small-cap pharmaceutical company may be the next in line as takeover fever heats up.
Is Novo Nordisk Stock a Sell Despite its 10% Price Rally in a Month?
NVO's 10% stock price rally masks deeper challenges as competition, restructuring and slower growth weigh on its outlook.
Viking Therapeutics, Inc. ( VKTX ) Outpaces Stock Market Gains: What You Should Know
In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $32.37, indicating a +2.65% shift from the previous trading day.
The Best Stocks to Invest $1,000 in Right Now
Buying these three stocks offers you instant diversification.
Viking Therapeutics, Inc. ( VKTX ) Beats Stock Market Upswing: What Investors Need to Know
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $27.88, denoting a +1.86% move from the preceding trading day.
Can NVO Maintain Obesity Leadership With Next-Generation Candidates?
Novo Nordisk is expanding beyond Wegovy and Ozempic with next-generation obesity candidates and strategic deals to defend its market lead.
Why This Beaten-Down GLP-1 Stock Could Be a Steal
There's more to this company than its performance on the stock market this year suggests.
Viking Therapeutics, Inc. ( VKTX ) Declines More Than Market: Some Information for Investors
In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $25.09, indicating a -5.78% shift from the previous trading day.
Brokers Suggest Investing in Viking Therapeutics ( VKTX ) : Read This Before Placing a Bet
Based on the average brokerage recommendation (ABR), Viking Therapeutics (VKTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Can Viking Therapeutics Hold Its Edge as Obesity Rivalry Heats Up?
VKTX faces rising pressure in the obesity drug race as Pfizer re-enters with a $4.9B Metsera deal and rivals scale up.
Pfizer Is Buying Weight Loss Biotech Metsera. Here's Why Viking Therapeutics Shareholders May Be Cheering.
Investors once speculated that Pfizer might consider acquiring Viking.
LLY vs. NVO: Which Obesity Drug Stock Is the Better Buy Now?
Eli Lilly's diversified pipeline, rapid tirzepatide growth and rising estimates give it the edge over Novo Nordisk in the obesity drug battle.
Viking Therapeutics, Inc. ( VKTX ) Falls More Steeply Than Broader Market: What Investors Need to Know
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $24.97, denoting a -4.88% move from the preceding trading day.
Can PFE Successfully Return to the Obesity Space With Metsera Buyout?
Pfizer strikes a $4.9B deal for Metsera, adding obesity drug candidates to its pipeline after scrapping danuglipron.
Can Novo Nordisk Hold Its Edge as the GLP-1 Battle With LLY Heats Up?
NVO gains ground in the GLP-1 battle as Ozempic outshines Trulicity in heart risk reduction and Rybelsus wins EU approval for added benefits.
Why Shares in Novo Nordisk Soared This Week
Positive results from the trial further indicate that the company is poised to win the next battle in the weight loss drug market.
Prediction: Viking Therapeutics Stock Will Double in Value Within the Next 12 Months
Viking's stock took a beating last month, and it has opened up a glorious buying opportunity for investors.
LLY's Orforglipron Tops NVO's Oral Pill in Diabetes Study: What's Next?
Eli Lilly's orforglipron beat NVO's Rybelsus in a 52-week diabetes study, showing stronger A1C and weight loss benefits.
NVO Stock Rises on Upbeat Phase III Data for Cagrilintide in Obesity
Novo Nordisk stock rises as its next-generation subcutaneous obesity treatment candidate, cagrilintide, delivers meaningful weight loss in a phase III obesity study.
AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?
Amgen's MariTide and Viking's VK2735 show promise in obesity, but pipeline strength and performance set the two biotech players apart.
